Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment.
BACKGROUND
Nail involvement is a common and distressing feature in the course of psoriasis. Although much progress has been made in the treatment of the disease, the presence of psoriasis in the nail continues to pose a challenge. In recent years, vitamin D3 analogs and a new formulation containing 8% clobetasol-17-propionate in a colourless nail lacquer vehicle have produced good results for the control of nail psoriasis.


OBJECTIVE
To determine the efficacy and safety of the combined treatment of 8% clobetasol-17-propionate in a lacquer vehicle and tacalcitol ointment in nail psoriasis.


METHODS
Fifteen patients with both nail bed and nail matrix psoriasis were included in the study. They were treated with a colourless nail lacquer containing 8% clobetasol-17-propionate applied at bedtime at the weekend, and with tacalcitol ointment under occlusion on the remaining days, for 6 months.


RESULTS
All 15 patients responded well to treatment. The therapeutic effect was very fast and directly related to the length of therapy. All nail alterations, including nail pain, were reduced, and the modified target Nail Psoriasis Severity Index fell by an average of 78% compared to baseline levels (+/-59.6, P < 0.0001).


CONCLUSIONS
Combined treatment with tacalcitol ointment and 8% clobetasol-17-propionate in a nail lacquer is a safe, effective treatment for nail bed and nail matrix psoriasis.
Sánchez Regaña
M
M
Psoriasis and Phototherapy Center, Department of Dermatology, Hospital Universitari Sagrat Cor. Teaching Unit, University of Barcelona, Barcelona, Spain. ez.reg@terra.es
Márquez Balbás
G
G
Umbert Millet
P
P
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002990:Clobetasol / Q000008:administration & dosage / Q000627:therapeutic use*; D004100:Dihydroxycholecalciferols / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009260:Nail Diseases / Q000188:drug therapy*; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D004100:Dihydroxycholecalciferols; D009824:Ointments; C023850:1 alpha,24-dihydroxyvitamin D3; D002990:Clobetasol